<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716806</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-015</org_study_id>
    <nct_id>NCT01716806</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)</brief_title>
  <official_title>A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study brentuximab vedotin to find out whether it is an effective treatment&#xD;
      for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study&#xD;
      will be older or will have other conditions that make them unable to have standard&#xD;
      chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with&#xD;
      other drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as&#xD;
      monotherapy and in combination with other agents as frontline therapy. There are 6 parts of&#xD;
      the study. The population to be studied includes treatment-naïve patients with classical&#xD;
      Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell&#xD;
      lymphoma (PTCL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2012</start_date>
  <completion_date type="Anticipated">January 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with complete response (CR) or (PR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR according to modified Lugano criteria per blinded independent central review (BICR) (Parts E and F)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only); up to approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only); up to approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of the first documentation of complete tumor response (CR) to the first documentation of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of study treatment to first documentation of tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the proportion of patients with CR, PR, or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR according to Lugano criteria per BICR (Parts E and F)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B symptom resolution rate</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with lymphoma-related B symptoms at baseline who achieve resolution of all B symptoms at any time during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of brentuximab vedotin</measure>
    <time_frame>Up to approximately 16 months. Cycle 1: predose, 30 minutes, and 24, 48, 168, and 336 hours post-dose; Cycles 2 and later (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brentuximab vedotin antitherapeutic antibodies (ATA)</measure>
    <time_frame>Up to approximately 18 months. Cycles 1, 2, 4, and every 4 cycles thereafter (through 1 month post last dose [Parts A, B, and C] or through 100 days post last dose of nivolumab [Part D only]): predose</time_frame>
    <description>Defined as the proportion of patients who develop ATA to brentuximab vedotin at any time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of nivolumab (Part D only)</measure>
    <time_frame>Up to approximately 16 months. Cycle 1: predose, 30 minutes, and 168 and 336 hours post-dose; Cycles 2, 4, and every 4 cycles thereafter (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nivolumab antitherapeutic antibodies (ATA) (Part D only)</measure>
    <time_frame>Up to approximately 18 months. Cycles 1, 2, 4, and every 4 cycles thereafter (through 100 days post last dose of nivolumab): predose</time_frame>
    <description>Defined as the proportion of patients who develop ATA to nivolumab at any time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Parts E and F only)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Defined as the time from start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part A: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F: Brentuximab Vedotin in PTCL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Part A: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
    <arm_group_label>Part E: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_label>Part F: Brentuximab Vedotin in PTCL Patients</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>70 mg/m^2 by IV infusion on Days 1 and 2 of 3-week cycle</description>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>375 mg/m^2 every 3 weeks by IV infusion</description>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>3 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parts A, B, C, and D: 60 years of age or older&#xD;
&#xD;
          -  Treatment-naive patients with histopathological diagnosis of classical Hodgkin&#xD;
             lymphoma (Parts A, B, C, D, and E)&#xD;
&#xD;
          -  Treatment-naive patients with CD30-expressing PTCL (Part F)&#xD;
&#xD;
          -  Ineligible for or have declined initial conventional combination chemotherapy for HL&#xD;
             (Parts A, B, C, and D)&#xD;
&#xD;
          -  Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E)&#xD;
             or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by:&#xD;
&#xD;
               -  A CIRS score of 10 or greater&#xD;
&#xD;
               -  Requiring assistance with or dependence on other for any instrumental activities&#xD;
                  of daily living (IADLs)&#xD;
&#xD;
          -  Measurable disease of at least 1.5 cm as documented by radiographic technique&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3&#xD;
             (Parts, A, B, C, E, and F) or less than or equal to 2 (Part D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic neurologic disease compromising IADLs or requiring medication&#xD;
&#xD;
          -  History of progressive multifocal leukoencephalopathy&#xD;
&#xD;
          -  Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the&#xD;
             first dose of brentuximab vedotin&#xD;
&#xD;
          -  Concurrent use of other investigational agents&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not&#xD;
             completed 4 weeks prior to first dose of study drug&#xD;
&#xD;
          -  History of another malignancy within 1 year before first dose of study drug (Parts E&#xD;
             and F only)&#xD;
&#xD;
          -  Part D only:&#xD;
&#xD;
               -  Received any prior immune-oncology therapy&#xD;
&#xD;
               -  History of known or suspected autoimmune disease&#xD;
&#xD;
               -  Prior allogeneic stem cell transplant&#xD;
&#xD;
               -  History of cerebral vascular event within 6 months of first dose of study drug&#xD;
&#xD;
               -  Active interstitial lung disease that is symptomatic or may interfere with the&#xD;
                  detection or management of suspected drug-related pulmonary toxicology&#xD;
&#xD;
               -  Known history of pancreatitis&#xD;
&#xD;
          -  Parts D, E, and F only:&#xD;
&#xD;
               -  Known cerebral/meningeal disease related to the underlying malignancy&#xD;
&#xD;
               -  Systemic treatment with corticosteroids or other immunosuppressive medications&#xD;
                  within 1 week of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sims, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melonie Hupp</last_name>
      <phone>205-975-2944</phone>
      <email>mjwest@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amitkumar Mehta</last_name>
      <phone>205-996-8400</phone>
      <email>anmehta@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amitkumar Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Alabama - Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Rodgers</last_name>
      <phone>251-445-8427</phone>
      <email>lrodgers@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Omar Alkharabsheh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alaska Urological Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Bergelin</last_name>
      <phone>480-256-5168</phone>
      <email>Jana.bergelin@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Horst U Klueppelberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Munoz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Donald J Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center / University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary A Sullivan</last_name>
      <phone>479-695-4168</phone>
      <email>msullivan@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>J. Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneliese Cadena</last_name>
      <phone>818-748-4797</phone>
      <email>Anneliese.cadena@providence.org</email>
    </contact>
    <investigator>
      <last_name>Raul Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi M Shankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Romero</last_name>
      <phone>626-256-4673</phone>
      <email>andromero@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew G Mei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group Inc.</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>John M Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Affiliates</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Wicker</last_name>
      <phone>888-737-7408</phone>
      <email>hwicker@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Pippas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists / Northside Hospital Cancer Institute</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duane Stallings</last_name>
      <phone>770-496-9400</phone>
      <email>duane.stallings@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo E Bordoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gina D'Amato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Veum</last_name>
      <phone>312-563-3710</phone>
      <email>Simone_p_veum@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Seo-Hyun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists / Advocate Lutheran General Hospital</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>American Oncology Networks LLC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cipriano</last_name>
      <phone>301-571-2016</phone>
      <email>jcipriano@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Flynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy G Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Ralph J Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Vincent</last_name>
      <phone>702-952-3400</phone>
      <email>Trisha.Vincent@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James D Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center/ Carol G. Simon Cancer Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Rice</last_name>
      <phone>973-971-5235</phone>
    </contact>
    <investigator>
      <last_name>Charles M Farber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-2681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Merz</last_name>
      <phone>732-235-4075</phone>
      <email>mm2778@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Evens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Garbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista French</last_name>
      <phone>585-275-4911</phone>
      <email>Krista_French@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Friedberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>James Essell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital / Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoof Giali</last_name>
      <phone>614-293-5655</phone>
      <email>Raoof.Giali@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Brammer</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Reneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute/Oncology Assc of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Christopher A Yasenchak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Kathryn Kolibaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Spencer H Shao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Arant-Daigle</last_name>
      <phone>817-261-4906</phone>
      <email>deborah.arant-daigle@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Scott L Fleischauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Illum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Ford</last_name>
      <phone>214-346-3517</phone>
      <email>Lindsay.Ford@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Johnson</last_name>
      <phone>(214)346-3508</phone>
      <email>Kelly.Johnson@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristi J McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Charles Kurkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Mark Redrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert L Ruxer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hun Ju Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M Viera</last_name>
      <phone>713-441-6011</phone>
      <email>jmoralesviera@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Sai Ravi Pingali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Matei P Socoteanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lijo John</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Ratnam</last_name>
      <phone>956-687-5150</phone>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Seton Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Vivian Cline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Dipti Patel-Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Lantis</last_name>
      <phone>804-828-2177</phone>
      <email>kllantis@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Beata Holkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Y Yazbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenandoah Oncology P.C.</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute/Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Aboulafia</last_name>
      <phone>206-341-1284</phone>
    </contact>
    <investigator>
      <last_name>David Aboulafia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariah Endres</last_name>
      <phone>608-263-1836</phone>
      <email>maendres3@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Chris Fletcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta / Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shyam Kumar Ravisankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Selay Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie Lachance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kelly Davison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>monomethylauristatin E</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>CD30-expression</keyword>
  <keyword>PTCL</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

